Never Miss a Breakthrough
Your most relevant papers across any scientific discipline, delivered directly to your inbox.
By creating a free account you’ll receive one daily email of paper matches based on your research profile. One-click unsubscribe in every email. See our Privacy Policy and Terms of Service.
Atomically accurate de novo design of antibodies with RFdiffusion
Bennett NR, Watson JL, Ragotte RJ et al.
Nov 2025
Confirmation of a Runaway Supermassive Black Hole via its Supersonic Bow Shock
van Dokkum P, Jennings C, Pasha I et al.
Dec 2025
Neutron scattering and thermodynamic evidence for emergent photons and fractionalization in a pyrochlore spin ice
Gao B, Desrochers F, Tam DW et al.
Jun 2025
Papers matched to your research, delivered on your schedule
Stay Current, Effortlessly
Set up once. Your most relevant papers are delivered automatically.
Describe your research
Write your project description in your own words: a hypothesis, a few sentences about your focus, or a full abstract. No keywords, no categories, no filtering. Just describe what you’re working on.
Research Project
CAR-T Cell Immunotherapy
Engineering next-generation CAR-T cells to overcome solid tumor resistance. Focused on improving antigen sensitivity, tumor microenvironment remodeling, and T cell persistence through novel co-stimulatory domain combinations.
Evaluated papers
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Science
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Science Translational Medicine
CAR T cells and T cell engagers for autoimmunity: lessons from hematology
Bone Marrow Transplantation
Searched, scored, and ranked
Every day, new papers are collected from four independent databases and evaluated against your research. Each candidate is scored on relevance, methods, novelty, and evidence strength. Only the top papers make the cut.
Your research digest
Your top papers arrive with a note explaining exactly why each one matters to your specific project. Not a generic abstract, but a paragraph written from the perspective of your research, delivered to your inbox every morning with notes explaining why each matters.
Inbox
The Lab Post
to me
7:00 AM
Your Research Digest
Their ultra-sensitive HIT receptor with CD80/4-1BBL costimulation eliminated tumors that evade standard CAR-T cells, directly relevant to your antigen-low targeting...
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Science · Read paper →
Built by a researcher, for researchers.
The Lab Post was founded by a researcher at the Johns Hopkins University School of Medicine. It was built to solve a problem every scientist faces: keeping up with the literature while running experiments.
Meet the founder →See what you'd receive
A real digest for one research project, delivered to your inbox.
Daily Research Digest · Mar 20, 2026
Hi Alex,
3 new papers today for CAR-T Cell Immunotherapy.
Demonstrates that heterogeneous CD70 expression in solid tumors is epigenetically regulated and often undetectable by conventional methods. Their ultra-sensitive HIT receptor with CD80/4-1BBL costimulation efficiently eliminated tumors that evade standard CAR-T cells, directly relevant to your antigen-low targeting strategy.
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Hanina SA, Spronken MI, Anstett DN et al. · Feb 2026 · Science
Read paper →
CAR-T cells engineered to secrete anti-VEGF single-chain variable fragments achieved superior efficacy against ovarian cancer and glioma models, outperforming both conventional CAR-T and combination anti-VEGF antibody therapy. The modular secretion approach could complement your tumor microenvironment remodeling work.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Gao TA, Shih RM, Clubb JD et al. · Mar 2026 · Science Translational Medicine
Read paper →
Reviews how CAR-T cell therapy and T cell engagers mediate sustained B cell depletion and long-term remissions in refractory autoimmune diseases, extending the therapeutic framework beyond oncology into areas relevant to your immunomodulation research.
CAR T cells and T cell engagers for autoimmunity: lessons from hematology
Bone Marrow Transplantation · Feb 2026 · Nature
Read paper →
That's your digest for today. See you tomorrow.
Go to DashboardYou're receiving this as an active subscriber. · Manage preferences
Daily Research Digest · Mar 20, 2026
Hi Alex,
3 new papers today for CAR-T Cell Immunotherapy.
Demonstrates that heterogeneous CD70 expression in solid tumors is epigenetically regulated and often undetectable by conventional methods. Their ultra-sensitive HIT receptor with CD80/4-1BBL costimulation efficiently eliminated tumors that evade standard CAR-T cells, directly relevant to your antigen-low targeting strategy.
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Hanina SA, Spronken MI, Anstett DN et al. · Feb 2026 · Science
Read paper →
CAR-T cells engineered to secrete anti-VEGF single-chain variable fragments achieved superior efficacy against ovarian cancer and glioma models, outperforming both conventional CAR-T and combination anti-VEGF antibody therapy. The modular secretion approach could complement your tumor microenvironment remodeling work.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Gao TA, Shih RM, Clubb JD et al. · Mar 2026 · Science Translational Medicine
Read paper →
Reviews how CAR-T cell therapy and T cell engagers mediate sustained B cell depletion and long-term remissions in refractory autoimmune diseases, extending the therapeutic framework beyond oncology into areas relevant to your immunomodulation research.
CAR T cells and T cell engagers for autoimmunity: lessons from hematology
Bone Marrow Transplantation · Feb 2026 · Nature
Read paper →
That's your digest for today. See you tomorrow.
Go to DashboardYou're receiving this as an active subscriber. · Manage preferences
You’re busy doing science.
We’ll bring you the papers that matter.
By creating a free account you’ll receive one daily email of paper matches based on your research profile. One-click unsubscribe in every email.